Evidence map›Paper›PMID 42440203›Full record

ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2026

Huachansu triggers mitochondrial apoptosis and ER stress to inhibit hepatocellular carcinoma progression.

Ximeng Li, Qiuying Yan, Qibiao Wu, Dan Dong, Runjing Zhang, Qinghai Meng, Changliang Xu, Yueyang Lai, Jiani Tan, Chengtao Yu and 5 more

Abstract read
In one paragraph

Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ximeng Li *The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Qiuying Yan *Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China.
Qibiao WuMacau University of Science and Technology, Avenida da Universidade, Macau, China.
Dan DongJiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China.
Runjing ZhangChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd., Shenzhen, China.
Qinghai MengJiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China.
Changliang XuJiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China.
Yueyang LaiJiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China.
Jiani TanJiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China.
Chengtao YuJiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China.
Liu LiJiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China.
Weixing ShenJiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China.
Qianjun ChenThe Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China. cqj55@163.com.
Haibo ChengJiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China. hbcheng_njucm@163.com.
Dongdong SunJiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China. sundd@njucm.edu.cn.

Funding

Key projects of Traditional Chinese Medicine Technology Development Plan of Jiangsu Province ZD202201Natural Science Foundation of Jiangsu Province BK20230452
6 · The paper itself

Abstract

Huachansu, derived from the dried skin glands of the Chinese toad (Bufo bufo gargarizans), has been used in traditional Chinese medicine for its anti-tumor properties, particularly in hepatocellular carcinoma (HCC). However, its molecular mechanisms remain unclear. This study investigates Huachansu's therapeutic potential by focusing on mitochondrial apoptosis and endoplasmic reticulum (ER) stress pathways. In vitro studies on HepG2 cells revealed that Huachansu (48-96 mg/mL for 24 h) disrupted mitochondrial function by elevating reactive oxygen species (ROS) generation (~ 83% and ~ 208% increase at 48 and 96 mg/mL, respectively) and reducing membrane potential. Molecular analyses showed upregulated pro-apoptotic Bax and ER stress effector CHOP alongside downregulated anti-apoptotic Bcl-2 and caspase family proteins, indicating PERK-ATF4 pathway activation. In vivo investigations using orthotopic and xenograft HCC mouse models demonstrated significant tumor volume (~ 25% at 2 g/kg and ~ 39% at 4 g/kg) and weight reduction with Huachansu treatment (2-4 g/kg/day, oral gavage for 18-21 days). Hepatic function improvements were evidenced by decreased serum ALT, AST, and LDH levels alongside increased superoxide dismutase (SOD) activity. Histopathological analyses confirmed reduced tumor progression and organ toxicity, while inflammatory cytokine profiling revealed diminished pro-inflammatory mediators. Mechanistically, Huachansu activated ER stress markers (PERK, ATF4) in tumor tissues without inducing systemic toxicity. These findings demonstrate that Huachansu exerts potent anticancer effects in HCC through concurrent induction of mitochondrial damage and ER stress activation. This study provides a mechanistic basis for Huachansu's traditional use and highlights its potential as a promising therapeutic agent for HCC treatment.

Indexed as

ApoptosisEndoplasmic reticulum stressHepatocellular carcinomaHuachansuMitochondrial damage

Identifiers

PMID42440203
PMCPMC13365083

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.